Arena Pharmaceuticals (ARNA) 4.55 $ARNA
Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 99.62 (+1.18), OREX: 5.55 (+0.10), ECYT: 5.26 (-0.02), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.55 (+0.10), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), QSII: 17.04 (+0.38), MDRX: 11.80 (+0.04), ARNA: 4.55 (+0.02)
Vivus' Qsymia Headed In The Wrong Direction
Clinically Sound Investor - at Seeking Alpha - Sat Feb 07, 4:44AM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Orexigen: Contrave Script Sales Dip. Why?
Spencer Osborne - at Seeking Alpha - Fri Feb 06, 5:36PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena Scripts Grow, But Pace Is Slower Than Needed
Spencer Osborne - at Seeking Alpha - Fri Feb 06, 5:31PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena's Belviq Keeps Up Momentum During A Flat Week
Clinically Sound Investor - at Seeking Alpha - Fri Feb 06, 3:05PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Why Arena Pharmaceuticals, Inc. Shares Jumped 24% in January
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 06, 9:17AM CST
ARNA data by YCharts What: Shares of Arena Pharmaceuticals , a biopharmaceutical company primarily focused on developing therapies for weight management and to treat autoimmune diseases, jumped 24% in January per S&P Capital IQ after...
ARNA: 4.55 (+0.02)
Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis
PR Newswire - Fri Feb 06, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Amgen Inc. (NASDAQ: AMGN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Advaxis Inc. (NASDAQ: ADXS). Free research report on Arena Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Arena%20P...amp;s=ARNA. On Thursday, February 05, 2015, the NASDAQ Composite ended at 4,765.10, up 1.03%, the Dow Jones Industrial Average advanced 1.20%, to finish the day at 17,884.88, and the S&P 500 closed at 2,062.52, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 813.68, up 1.64%, with the index also advancing 4.56% in the last three months. Register for your complimentary reports at the links given below.
ADXS: 7.18 (+0.06), ZIOP: 9.64 (-0.35), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), ARNA: 4.55 (+0.02)
The South Korean Market For Arena's Belviq May Be Larger Than Expected
Jim Roof - at Seeking Alpha - Thu Feb 05, 12:19PM CST
ARNA: 4.55 (+0.02)
Arena's Partner May Need To Advertise More
Spencer Osborne - at Seeking Alpha - Wed Feb 04, 11:37AM CST
ARNA: 4.55 (+0.02)
Arena's Belviq Approved In South Korea - Can It Change The Dynamics?
Spencer Osborne - at Seeking Alpha - Wed Feb 04, 10:33AM CST
ARNA: 4.55 (+0.02)
Critical Alerts For El Pollo Loco, Office Depot, ITT Education, ConocoPhillips and Arena Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Feb 04, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LOCO, ODP, ESI, COP and ARNA.
ESI: 7.58 (-0.29), COP: 69.88 (+1.84), LOCO: 24.20 (+0.06), ODP: 9.59 (-0.02), ARNA: 4.55 (+0.02)
With Flat Qsymia Sales, Vivus May Shift Focus To Stendra/Spedra
Spencer Osborne - at Seeking Alpha - Tue Feb 03, 1:44PM CST
NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Belviq cleared for sale in South Korea
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:34AM CST
ARNA: 4.55 (+0.02)
Arena Pharmaceuticals Announces Marketing Approval in South Korea of BELVIQ® (lorcaserin HCl) for Weight Management
PR Newswire - Tue Feb 03, 4:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Ildong Pharmaceutical Co., Ltd., has informed Arena that the Ministry of Food and Drug Safety has approved BELVIQ® (lorcaserin HCl) for marketing for weight management in South Korea. Ildong will market and distribute BELVIQ in South Korea under its marketing and supply agreement with Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH. In connection with the approval, Arena GmbH will receive a milestone payment of $3.0 million from Ildong.
ARNA: 4.55 (+0.02)
Orexigen's Contrave Prescription Growth Slowing, But Still Good
Clinically Sound Investor - at Seeking Alpha - Mon Feb 02, 5:37PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena Pharmaceuticals' Belviq Set To Surge In 2015
Jim Roof - at Seeking Alpha - Mon Feb 02, 12:47PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Orexigen: Contrave Scripts Slow Down - Competition Lowers Price
Spencer Osborne - at Seeking Alpha - Mon Feb 02, 12:05PM CST
OREX: 5.55 (+0.10), ARNA: 4.55 (+0.02)
Arena's Belviq Sales Need Better Pace
Spencer Osborne - at Seeking Alpha - Mon Feb 02, 11:57AM CST
ARNA: 4.55 (+0.02)
Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 99.62 (+1.18), OREX: 5.55 (+0.10), ECYT: 5.26 (-0.02), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.55 (+0.10), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), QSII: 17.04 (+0.38), MDRX: 11.80 (+0.04), ARNA: 4.55 (+0.02)
Vivus' Qsymia Headed In The Wrong Direction
Clinically Sound Investor - at Seeking Alpha - Sat Feb 07, 4:44AM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Orexigen: Contrave Script Sales Dip. Why?
Spencer Osborne - at Seeking Alpha - Fri Feb 06, 5:36PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena Scripts Grow, But Pace Is Slower Than Needed
Spencer Osborne - at Seeking Alpha - Fri Feb 06, 5:31PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena's Belviq Keeps Up Momentum During A Flat Week
Clinically Sound Investor - at Seeking Alpha - Fri Feb 06, 3:05PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Why Arena Pharmaceuticals, Inc. Shares Jumped 24% in January
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 06, 9:17AM CST
ARNA data by YCharts What: Shares of Arena Pharmaceuticals , a biopharmaceutical company primarily focused on developing therapies for weight management and to treat autoimmune diseases, jumped 24% in January per S&P Capital IQ after...
ARNA: 4.55 (+0.02)
Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis
PR Newswire - Fri Feb 06, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Amgen Inc. (NASDAQ: AMGN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Advaxis Inc. (NASDAQ: ADXS). Free research report on Arena Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Arena%20P...amp;s=ARNA. On Thursday, February 05, 2015, the NASDAQ Composite ended at 4,765.10, up 1.03%, the Dow Jones Industrial Average advanced 1.20%, to finish the day at 17,884.88, and the S&P 500 closed at 2,062.52, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 813.68, up 1.64%, with the index also advancing 4.56% in the last three months. Register for your complimentary reports at the links given below.
ADXS: 7.18 (+0.06), ZIOP: 9.64 (-0.35), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), ARNA: 4.55 (+0.02)
The South Korean Market For Arena's Belviq May Be Larger Than Expected
Jim Roof - at Seeking Alpha - Thu Feb 05, 12:19PM CST
ARNA: 4.55 (+0.02)
Arena's Partner May Need To Advertise More
Spencer Osborne - at Seeking Alpha - Wed Feb 04, 11:37AM CST
ARNA: 4.55 (+0.02)
Arena's Belviq Approved In South Korea - Can It Change The Dynamics?
Spencer Osborne - at Seeking Alpha - Wed Feb 04, 10:33AM CST
ARNA: 4.55 (+0.02)
Critical Alerts For El Pollo Loco, Office Depot, ITT Education, ConocoPhillips and Arena Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Feb 04, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LOCO, ODP, ESI, COP and ARNA.
ESI: 7.58 (-0.29), COP: 69.88 (+1.84), LOCO: 24.20 (+0.06), ODP: 9.59 (-0.02), ARNA: 4.55 (+0.02)
With Flat Qsymia Sales, Vivus May Shift Focus To Stendra/Spedra
Spencer Osborne - at Seeking Alpha - Tue Feb 03, 1:44PM CST
NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Belviq cleared for sale in South Korea
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:34AM CST
ARNA: 4.55 (+0.02)
Arena Pharmaceuticals Announces Marketing Approval in South Korea of BELVIQ® (lorcaserin HCl) for Weight Management
PR Newswire - Tue Feb 03, 4:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Ildong Pharmaceutical Co., Ltd., has informed Arena that the Ministry of Food and Drug Safety has approved BELVIQ® (lorcaserin HCl) for marketing for weight management in South Korea. Ildong will market and distribute BELVIQ in South Korea under its marketing and supply agreement with Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH. In connection with the approval, Arena GmbH will receive a milestone payment of $3.0 million from Ildong.
ARNA: 4.55 (+0.02)
Orexigen's Contrave Prescription Growth Slowing, But Still Good
Clinically Sound Investor - at Seeking Alpha - Mon Feb 02, 5:37PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Arena Pharmaceuticals' Belviq Set To Surge In 2015
Jim Roof - at Seeking Alpha - Mon Feb 02, 12:47PM CST
OREX: 5.55 (+0.10), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Orexigen: Contrave Scripts Slow Down - Competition Lowers Price
Spencer Osborne - at Seeking Alpha - Mon Feb 02, 12:05PM CST
OREX: 5.55 (+0.10), ARNA: 4.55 (+0.02)
Arena's Belviq Sales Need Better Pace
Spencer Osborne - at Seeking Alpha - Mon Feb 02, 11:57AM CST
ARNA: 4.55 (+0.02)
